About Cerus

Cerus Corporation is a biopharmaceutical company focused on the development and commercialization of the INTERCEPT Blood System. The INTERCEPT system is designed to inactivate blood-borne pathogens in donated blood components intended for transfusion. The company currently markets the INTERCEPT system for both platelets and plasma in Europe and, through distributors and licensees, in countries around the world that recognize the CE mark. The company is also in Phase I clinical trials for development of the INTERCEPT system for red blood cells in the United States.

Find out more about Cerus Corporation

© 2012 Cerus Corporation. All Rights Reserved.

Use of the INTERCEPT Blood System in the United States is limited by Federal law to investigational use. If you are a resident of the U.S., please click here.

The information on this site is not country-specific, and may contain information that is outside the approved indications for the country in which you are located. The INTERCEPT Blood System is CE marked for use with platelets and plasma. No pathogen inactivation system has been shown to inactivate all pathogens.

Legal Info | Privacy Policy